https://www.barchart.com/stocks/quotes/CTMX/top-trade-alerts
Find top picks, top trade alerts and trading ideas for Cytomx Thera. Premier members get access to stock trading strategies from Barchart.
top tradealertscytomxtherastock
https://finviz.com/news/280259/cytomx-stock-rises-31-in-a-month-heres-what-you-should-know
Stock screener for investors and traders, financial visualizations.
cytomxstockrisesmonth
https://huntscanlon.com/on-partners-recruits-chief-business-officer-for-cytomx-therapeutics/
Nov 26, 2025 - Partner Suzanne Zebedee of ON Partners recently placed Rachael Lester as senior vice president and chief business officer of NASDAQ-traded CytomX...
chief business officerpartnersrecruitscytomxtherapeutics
https://www.macrotrends.net/stocks/charts/CTMX/cytomx-therapeutics/cash-flow-statement
Ten years of annual cash flow statements for CytomX Therapeutics (CTMX). The cash flow statement is a summary of the cash inflows and outflows for a business...
cash flow statementcytomxtherapeuticsmacrotrends
https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/
CX-2051 is under clinical development by CytomX Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
metastatic colorectal cancercxcytomxtherapeuticslikelihood
https://www.macrotrends.net/stocks/charts/CTMX/cytomx-therapeutics/gross-profit
CytomX Therapeutics gross profit from 2014 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly...
gross profitcytomxtherapeuticsmacrotrends
https://www.pharmaceutical-technology.com/data-insights/cx-801-cytomx-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
CX-801 is under clinical development by CytomX Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
cxcytomxtherapeuticsheadneck
https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-gastric-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-318700&utm_campaign=recommended-articles-pi
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Gastric Cancer.
gastric cancercxcytomxtherapeuticslikelihood